An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
Background: Gene therapies can treat, prevent, or cure a disease by changing the expression of a person’s genes. They are an innovative strategy for treating genetic disorders; however, they are still emerging on the market access and in the healthcare system. Health technology assessment (HTA) agen...
Guardado en:
Autores principales: | Michał Pochopień, Ewelina Paterak, Emilie Clay, Justyna Janik, Samuel Aballea, Małgorzata Biernikiewicz, Mondher Toumi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/754b4c674be641ef872d82a64d8b4e17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe
por: Katarzyna Jabłońska, et al.
Publicado: (2021) -
Problems of Identification and Analysis of Transaction Costs at the Economic Entity Level
por: Herasymenko Tetiana V.
Publicado: (2021) -
Reinforcing Collaboration and Harmonization to Unlock the Potentials of Advanced Therapy Medical Products: Future Efforts Are Awaited From Manufacturers and Decision-Makers
por: Tingting Qiu, et al.
Publicado: (2021) -
SEPARATION OF FIXED AND VARIABLE COSTS FROM MIXED COSTS AT A WATER AND SEWERAGE OPERATOR
por: Árpád-Zoltán Fülöp, et al.
Publicado: (2021) -
Vocational training costs and economic benefits: exploring the interactions
por: Natalia Samoliuk, et al.
Publicado: (2021)